Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
Key Points
Agios stock surged after FDA granted priority review for mitapivat in sickle cell disease.
Mitapivat showed mixed Phase 3 results, and competition is coming from Novo Nordisk.
- 10 stocks we like better than Agios Pharmaceuticals ›
Agios Pharmaceuticals (NASDAQ: AGIO) stock rose by 13.8% during the week through Friday morning. It's a move driven by the Food and Drug Administration's (FDA) announcement that it would grant priority review for Agios' key drug, an oral pyruvate kinase (PK) activator, mitapivat, in sickle cell disease (SCD).
Agios and mitapivat
Mitapivat is already approved to treat PK deficiency and thalassemia in adults, and Agios is seeking approval as the first oral pyruvate kinase (PK) activator for sickle cell disease. PK activators work to improve the health of red blood cells and reduce sickle cell formation, resulting in a reduction in blood vessel blockages, anemia, and the sickle cell pain crises (SCPCs), events that create severe discomfort for sufferers.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Mitapivat trial results
It's here where it gets a bit complicated. In November, management released mixed results from the Phase 3 RISE UP trial of mitapivat in SCD.
- The primary endpoint, hemoglobin response, and the key secondary endpoint, change from baseline in hemoglobin concentration, were met.
- Mitapivat did "not meet statistical significance in the primary endpoint of annualized rate of SCPCs."
The failure to meet the primary endpoint of SCPC reduction is an obvious concern, especially given that Novo Nordisk later reported that its rival oral pyruvate kinase-R (PKR) activator improved hemoglobin response and demonstrated a statistically meaningful reduction in crisis events.
Fast forward to June, and Agios provided more detailed data from the RISE UP trial, noting that among patients in the mitapivat-treated group who reported a response in hemoglobin, there was a "clinically meaningful benefit across measures of sickle cell pain crises, fatigue, and other patient-reported outcomes."
Image source: Getty Images.
Where next for Agios Pharmaceuticals
An accelerated approval (decision due by Nov. 1) would be a major plus. Still, to gain full approval later, Agios has to demonstrate success in the confirmatory REIGNITE 3 trial, which the FDA requires as part of the accelerated approval process.
There's still plenty for Agios to do, and competition is coming from a formidable rival, but Agios appears to have good chances of getting mitapivat approved for SCD this year.
Should you buy stock in Agios Pharmaceuticals right now?
Before you buy stock in Agios Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Agios Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $407,651!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,252,823!*
Now, it’s worth noting Stock Advisor’s total average return is 922% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of July 10, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
